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To the Editor: While it is suggested that, in addition to
hyperglycaemia, glucose variability can contribute to the
severity and development of diabetic neuropathy [1], it is not
related to the development of retinopathy and nephropathy in
type 1 diabetes [1, 2]. To determine any additional effect of
glucose variability—above that assessed by HbA1c and mean
glucose—on peripheral and autonomic diabetic neuropathy,
we used the datasets collected during the DCCT (available at
www.gcrc.med.umn.edu/gcrc/downloads/dcct.html,a c c e s s e d
23–27 January 2009) [3].
We studied the effect of glucose variability on the main
neurological endpoint of the DCCT, i.e. confirmed clinical
neuropathy, and on the DCCT-defined secondary endpoints
separately: clinical neuropathy, abnormal nerve conduction
studies, and abnormal autonomic function [4]. In addition,
we determined its effect on the subvariables median motor
F-wave latency, sural amplitude, sensory signs and beat-to-
beat heart-rate variation (with Valsalva ratio <1.5), as these
variables tend to be the first affected by diabetes. We
included only data from baseline to 4 years (autonomic
function data) or 5 years of follow-up in the analyses as
more than 50% of the patients did not have records of
glucose data after 5 years of follow-up.
We assessed glycaemic variables from seven-point blood
glucose profiles collected every 3 months. We included all
glucose profiles with five observations or more during the
24 h period, extrapolating missing values from the surround-
ing points [5]. Mean blood glucose was calculated by the
AUC using the trapezoidal rule [6]. Variability of blood
glucose (within-day SD) was calculated as the SD of daily
blood glucose around the mean from each quarterly visit and
the mean amplitude of glycaemic excursions (MAGE) [7].
Last, we calculated the mean SD from individual glucose
data transformed to a symmetric distribution according to
Kovatchev [8]. Glucose variability from baseline to 4 or
5 years was assessed as the mean SD and mean MAGE from
the first quarter to the 16th or 20th quarter of follow-up,
respectively.
The main characteristics of the patients in the group
analysed for confirmed clinical neuropathy are listed in
Table 1. Of the 1,441 patients in total, 1,160 were included
in this specific analysis. Ninety-two patients were excluded
from the analysis because they had a positive score at
baseline and 189 patients had missing data on confirmed
clinical neuropathy at baseline (n=3) or at 5 years (n=186).
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specific neuropathy groups are listed in Table 2. Patients
with a positive baseline score on the neuropathy variable
studied were excluded from analysis.
Logistic regression analysis adjusted for age (years), sex,
disease duration (years), randomised treatment (conven-
tional versus intensive) and prevention cohort (primary
versus secondary), showed no effect of glucose variability,
Table 1 Patient characteristics in the group analysed for confirmed clinical neuropathy
Characteristic Confirmed clinical neuropathy (5 years) p value
Yes (n=108) No (n=1,052)
Age at baseline (years) 28.28 (6.77) 26.40 (7.10) 0.008
Male sex, n (%) 52 (48) 533 (53) 0.38
Diabetes duration at baseline (months) 79.59 (45.62) 68.60 (49.79) 0.02
Conventional treatment, n (%) 80 (74) 517 (49) <0.001
Primary prevention cohort, n (%) 35 (32) 503 (48) 0.002
HbA1c (%) 9.10 (1.58) 8.08 (1.43) <0.001
Mean glucose (mmol/l) 13.51 (3.33) 11.52 (3.78) <0.001
MAGE (mmol/l) 8.00 (1.96) 7.55 (1.90) 0.02
SD 4.24 (0.89) 4.05 (0.93) 0.04
SD TF 0.75 (0.17) 0.81 (0.16) <0.001
Data are means (SD), unless stated otherwise
For this analysis patients with a positive or missing score for confirmed clinical neuropathy at baseline were excluded (neuropathy n=92; missing n=3)
Patients with a missing score at 5 years are also excluded from the analysis (n=186)
p values are comparisons between groups (independent samples t test)
SD TF, standard deviation obtained from glucose data transformed according to Kovatchev et al.: transformed blood glucose ¼ 1:794 
ð log BG fg ½ 
1:026   1:861Þ, where BG is blood glucose in mmol/l [8]
Table 2 Binary logistic regression analysis relating the effect of different glycaemic variables to neurological complications, as defined by the
DCCT
Model Confirmed clinical
neuropathy
a n=108/1,160
c
Clinical neuropathy
a
n=148/1,113
c
Autonomic neuropathy
b
n=79/1,258
c
Abnormal nerve conduction
a
n=207/813
c
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
HbA1c 1.64 (1.37–1.95) <0.001 1.40 (1.20–1.64) <0.001 1.51 (1.23–1.85) <0.001 1.62 (1.39–1.90) <0.001
AUC 1.17 (1.09–1.26) <0.001 1.13 (1.05–1.21) 0.001 1.15 (1.05–1.26) 0.003 1.15 (1.07–1.23) <0.001
SD 1.07 (0.83–1.35) 0.67 0.95 (0.77–1.18) 0.66 1.30 (0.99–1.70) 0.06 1.17 (0.96–1.42) 0.12
SD (HbA1c) 0.86 (0.67–1.10) 0.24 0.82 (0.66–1.03) 0.08 1.08 (0.82–1.44) 0.58 0.94 (0.75–1.14) 0.46
SD (AUC) 0.85 (0.65–1.10) 0.21 0.78 (0.61–0.99) 0.04 1.09 (0.80–1.48) 0.59 0.95 (0.76–1.19) 0.68
MAGE 1.06 (0.96–1.20) 0.23 1.01 (0.91–1.11) 0.90 1.16 (1.03–1.30) 0.01 1.07 (0.98–1.17) 0.14
MAGE (HbA1c) 1.00 (0.89–1.12) 0.95 0.96 (0.86–1.06) 0.37 1.09 (0.96–1.23) 0.18 0.98 (0.90–10.8) 0.74
MAGE (AUC) 1.00 (0.88–1.12) 0.93 0.94 (0.85–1.05) 0.29 1.10 (0.97–1.25) 0.13 1.00 (0.91–1.10) 0.93
SD TF 0.14 (0.04–0.52) 0.003 0.15 (0.05–0.48) 0.001 0.63 (0.13–3.07) 0.57 0.16 (0.06–0.47) 0.001
SD TF (HbA1c) 0.36 (0.09–1.37) 0.13 0.25 (0.07–0.86) 0.03 1.42 (0.26–7.71) 0.68 0.62 (0.20–1.87) 0.39
SD TF (AUC) 0.33 (0.08–1.39) 0.13 0.26 (0.08–0.87) 0.03 1.27 (0.25–6.29) 0.77 0.61 (0.19–1.94) 0.40
SD (HbA1c), SD (AUC), MAGE (HbA1c), MAGE (AUC), SD TF (HbA1c) and SD TF (AUC) are six distinct models denoting additional
adjustment for (HbA1c) or (AUC)
All models were adjusted for baseline covariates (sex, age, disease duration, prevention cohort, randomised treatment)
HbA1c, AUC, SD, MAGE and SD TF represent means from quarterly visits:
a1–20;
b1–16
cPatients with a positive neuropathy score at 5 years/complete analysis group per variable
SD TF, standard deviation obtained from glucose data transformed according to Kovatchev et al.: transformed blood glucose ¼ 1:794 
ð log BG fg ½ 
1:026   1:861Þ, where BG is blood glucose in mmol/l [8]
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point glucose profiles from quarterly visits 1–20 (first
5 years), on confirmed clinical neuropathy, clinical neurop-
athy alone or nerve conduction abnormalities (Table 2).
Dividing the variables in quartiles and performing the
analyses per randomisation group did not change the
outcome (data not shown).
No effect of glycaemic variability on clinical neuropathy
was seen, with the exception of a small protective effect of
the SD adjusted for AUC (Table 2). In addition, no effect
of glycaemic variability was seen on the incidence of
sensory signs (SD OR 1.00, 95% CI 0.82–1.22, p=0.99;
MAGE OR 1.02, 95% CI 0.93–1.12, p=0.69) as well as in
separate analysis of the F-wave latency of the median nerve
(SD OR 1.12, 95% CI 0.84–1.49, p=0.44; MAGE OR 1.03,
95% CI 0.90–1.17, p=0.67) and the amplitude of the sural
nerve (SD OR 1.27, 95% CI 1.00–1.60, p=0.05; MAGE
OR 1.05, 95% CI 0.95–1.17, p=0.34). Glycaemic variabil-
ity seemed to have an effect on autonomic neuropathy, but
this effect disappeared when adjusting the model for HbA1c
or AUC (Table 2). Analysing both randomisation groups
separately also did not reveal a relation over HbA1c (data
not shown). Separate examination of the three autonomic
function variables showed that only for beat-to-beat heart
rate variation during a Valsalva manoeuvre did the effect
remain significant when adjusting for mean glucose (SD
OR 2.64, 95% CI 1.17–5.94, p=0.02; MAGE OR 1.42,
95% CI 1.07–1.90, p=0.02), but not when adjusting for
HbA1c (SD OR 1.84, 95% CI 0.90–3.76, p=0.09; MAGE
OR 1.30, 95% CI 0.98–1.72, p=0.07). There was no effect
of glycaemic variability on beat-to-beat heart-rate variation
during deep breathing and postural blood pressure testing
(data not shown). Transformation of the individual glucose
data according to Kovatchev [8] did not alter the results
(Table 2).
These results are in line with earlier analysis of DCCT
data describing no influence of glycaemic variability on
the development or progression of retinopathy and
nephropathy [2]. Bragd and colleagues found that glucose
variability (SD) was a borderline predictor of the inci-
dence of peripheral neuropathy in 100 patients with type 1
diabetes and with a follow-up period of 11 years (p=0.07;
HR 1.73, range 0.94–3.19) [1]. Peripheral neuropathy in
their study was defined as sensory neuropathy, as
indicated by monofilament testing and an abnormal
electromyography (EMG) and/or vibration test. This same
study showed a significant relationship between SD and
the prevalence of peripheral neuropathy (p=0.03; OR
2.34, range 1.06–5.20), perhaps suggesting that the
nervous system might be particularly susceptible to
glycaemic fluctuations [1].
What strengthens our results is that we did not find a
relationship between glucose variability and sensory signs
or median motor F-wave latency and sural amplitude, the
earliest indicators of diabetic neuropathy. As diabetic
neuropathy is mostly a small-fibre disease, sensory signs
are usually the presenting sign of the disease and they are a
stable and reliable measure of disease status or progression
[9]. Although EMG studies measure large-fibre function,
median motor F-wave latency and sural amplitude are the
most sensitive of all EMG measures to detect diabetic
neuropathy [10, 11].
A limitation of this study is that the variables are
calculated from seven point glucose curves by self-
monitoring. Continuous glucose monitoring might detect
fluctuations occurring between two measurements that would
be missed by self-monitoring of blood glucose. Another
difficulty is that the neuropathy variables were infrequently
scored. Possibly the DCCT/Epidemiology of Diabetes
Interventions and Complications (EDIC) follow-up will
provide more endpoints as the same neuropathy variables
assessed in the DCCT are measured in years 13 or 14 of its
follow-up (2007–2008; www.niddkrepository.org,a c c e s s e d
23–27 January 2009). These data have not yet been released.
In conclusion, glucose variability was not a risk factor
separate from HbA1c or mean glucose in the development
of diabetic peripheral neuropathy in the DCCT.
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